Company news
Ptc Therapeutics, Inc. (NASDAQ:PTCT) news
Ptc Therapeutics, Inc. news releases on 6ix. Latest, Sep 21, 2026: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Press releases & updates
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
September 21, 2026
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
August 24, 2026
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
August 12, 2026
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
July 30, 2026
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
July 16, 2026
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
June 14, 2026
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
June 15, 2026
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Ardena Strengthens Executive Team to Drive its Next Phase of Growth
May 4, 2026
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
April 28, 2026
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 21, 2026
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
March 24, 2026
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 19, 2026
PTC Therapeutics Provides Regulatory Update on Translarna™
February 12, 2026
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
February 5, 2026
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
January 12, 2026
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 8, 2026
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
December 21, 2025
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
December 10, 2025
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
December 1, 2025
PTC Therapeutics to Host R&D Day
November 19, 2025
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 3, 2025
PTC Therapeutics to Participate at Upcoming Investor Conferences
October 30, 2025
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results
October 20, 2025
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 9, 2025
RareMed Announces Expansion of Relationship with PTC Therapeutics
September 2, 2025
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
August 18, 2025
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 6, 2025
Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin)
July 30, 2025
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
July 27, 2025
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results
July 20, 2025
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
June 22, 2025
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 5, 2025
PTC518 PIVOT-HD Study Achieves Primary Endpoint
May 4, 2025
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
April 24, 2025
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
April 16, 2025
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
March 27, 2025
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
March 19, 2025
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
PTC Therapeutics to Participate in Upcoming Investor Conferences
February 19, 2025
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
February 18, 2025
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
January 12, 2025
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 22, 2024
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
December 18, 2024
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
December 1, 2024
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
November 26, 2024
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
November 25, 2024
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
November 12, 2024